Related Experiment Videos
Problems and benefits of an antibiotic compassionate therapy program
G B Calandra1, J P Garelik, P T Kohler
1Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486.
Reviews of Infectious Diseases
|November 1, 1987
Summary
Compassionate therapy offers life-saving treatments but presents challenges for physicians and pharmaceutical companies. Streamlining regulatory processes and improving data collection are crucial for its continued success.
Area of Science:
- Medical Ethics
- Pharmaceutical Sciences
- Clinical Trial Management
Background:
- Compassionate therapy provides access to essential medications for patients with unmet needs.
- This therapeutic approach can create administrative and data-related challenges for both healthcare providers and drug manufacturers.
Purpose of the Study:
- To examine the procedural complexities and outcomes associated with compassionate use of imipenem/cilastatin.
- To identify challenges faced by physicians and pharmaceutical companies in compassionate therapy programs.
- To propose improvements for enhancing compassionate use drug programs.
Main Methods:
- Case study analysis of compassionate use protocols for imipenem/cilastatin.
- Review of physician and pharmaceutical company experiences with regulatory and data reporting requirements.
- Evaluation of patient outcomes and safety within the context of complex medical histories.
Main Results:
- Physicians experience delays in drug acquisition and difficulties completing regulatory forms.
- Pharmaceutical companies face challenges with document retrieval, data utilization for registration, and safety assessments in complex patient populations.
- Despite challenges, compassionate therapy demonstrates benefits for all stakeholders.
Conclusions:
- Compassionate therapy programs are valuable and should be continued.
- Streamlining case report forms and ensuring diligent completion by investigators can improve program efficiency.
- Addressing administrative and data management hurdles is key to optimizing compassionate drug access.